Patient booklets
Is there anything else I can offer to my patients to provide additional support?
Two patient booklets have been created; one for patients with treatment-resistant depression (TRD), and one for adult patients experiencing a psychiatric emergency due to major depressive disorder (MDD-PE), to try and answer any remaining questions your patients may have following their appointment.
.png?width=265&height=218&format=webp&quality=60)
.png?width=265&height=218&format=webp&quality=60)
NEW
Learn more about what makes SPRAVATO® a breakthrough therapy*[1][2]
Connect with peers who have SPRAVATO® prescribing experience.
Access live and recorded meetings
* Following the approval of the SSRI fluoxetine in 1987, approved treatments have continued to primarily target the monoaminergic system.[3][4] In contrast, SPRAVATO® is an antagonist of the NMDA glutamate receptor.[5]
Abbreviations
MDD-PE, psychiatric emergency due to major depressive disorder; NMDA, N-methyl-D-aspartate; SSRI, selective serotonin reuptake inhibitor; TRD, treatment-resistant depression.
[Insert local AE reporting text as required]
[Insert link to PI]
[Request information from the Janssen Medical Information team]
[Contact your Janssen Account Manager or Medical Scientific Liaison Manager]
